BGM
NRIX icon

Burkehill Global Management’s Nurix Therapeutics NRIX Stock Holding History

Burkehill Global Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.89M Hold
118,972
– – 0.1% 113
2026
Q1 		$1.84M Hold
118,972
– – 0.09% 129
2025
Q4 		$2.26M Buy
+118,972
New +$1.71M 0.15% 111

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Burkehill Global Management's NRIX Position: Q2 2026 in Review

Burkehill Global Management held its Nurix Therapeutics (NRIX) position steady in Q2 2026 at 118,972 shares worth $2.89M. The position accounts for 0.1% of the portfolio, ranked #113.

Burkehill Global Management first reported a position in NRIX in Q4 2025 and has held it in 3 quarters since. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Burkehill Global Management held 118,972 shares of Nurix Therapeutics worth $2.89M as of Q2 2026.
  • Burkehill Global Management left its Nurix Therapeutics share count unchanged in Q2 2026.
  • Nurix Therapeutics made up 0.1% of Burkehill Global Management's portfolio in Q2 2026, its #113 holding.
  • Burkehill Global Management first reported a position in Nurix Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Burkehill Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.